Diagnosis and classification of drug-induced autoimmunity (DIA)

Journal of Autoimmunity

Volumn 48-49, Issue , 2014, Pages 66-72

  Xiao, Xiao ^a   Chang, Christopher ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti histone antibodies; Anti nuclear antibodies; Anti phospholipid syndrome; Drug induced lupus; Procainamide; Systemic lupus erythematosus

Indexed keywords

ANTIALLERGIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIMIGRAINE AGENT; ANTIPARKINSON AGENT; ANTIRHEUMATIC AGENT; AROMATASE INHIBITOR; ATYPICAL ANTIPSYCHOTIC AGENT; CARDIAC AGENT; CHELATING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC AGENT; METRIZAMIDE; MINOXIDIL; OXYPHENISATINE; PERPHENAZINE; PSORALEN;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DRUG INDUCED AUTOIMMUNE DISEASE; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-HISTONE ANTIBODIES; ANTI-NUCLEAR ANTIBODIES; ANTI-PHOSPHOLIPID SYNDROME; DRUG INDUCED LUPUS; PROCAINAMIDE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; HYDRALAZINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCAINAMIDE; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 84895885395     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.01.005     Document Type: Article

References (123)

1. Vedove C.D., Del Giglio M., Schena D., Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009, 301:99-105.
2. Chang C., Gershwin M.E. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011, 34:357-374.
3. Reinhardt D.J., Waldron J.M. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. JAm Med Assoc 1954, 155:1491-1492.
4. Rubin R.L. Drug-induced lupus. Toxicology 2005, 209:135-147.
5. Yokogawa N., Vivino F.B. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009, 19:338-347.
6. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, 10:46-50.
7. Williams E.L., Gadola S., Edwards C.J. Anti-TNF-induced lupus. Rheumatology 2009, 48:716-720.
8. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo clinic. Mayo Clin Proc 2009, 84:979-984.
9. Deeks E.D. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs 2013, 73:75-97.
10. Wilkerson E., Hazey M.A., Bahrami S., Callen J.P. Golimumab-exacerbated subacute cutaneous lupus erythematosus. Arch Dermatol 2012, 148:1186-1190.
11. Schlienger R.G., Bircher A.J., Meier C.R. Minocycline-induced lupus. A systematic review. Dermatology 2000, 200:223-231.
12. Alloway J.A., Salata M.P. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 1995, 24:315-322.
13. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French National Survey. Arthritis Res Ther 2005, 7:R545-R551.
14. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008, 37:381-387.
15. Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. JEur Acad Dermatol Venereol 2007, 21:17-24.
16. Aloush V., Litinsky I., Caspi D., Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum 2006, 36:4-9.
17. Burlingame R.W., Rubin R.L. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. JClin Invest 1991, 88:680-690.
18. Borchers A.T., Keen C.L., Gershwin M.E. Drug-induced lupus. Ann N Y Acad Sci 2007, 1108:166-182.
19. Rotoli B., Formisano S., Alfinito F. Autoimmune haemolytic anaemia associated with cimetidine. Lancet 1979, 314:583.
20. Brenner W., Gschnait F. Cinnarizin - an up to now unrecognized inducer of a lupus erythematosus-like syndrome. Hautarzt 1978, 29:392-394.
21. Perez-Mateo M., Sillero C., Perez A., Vazquez N. Vasculitis caused by benoxaprofen. Med Clin (Barc) 1983, 81:459.
22. Sanford-Driscoll M., Knodel L.C. Induction of hemolytic anemia by nonsteroidal antiinflammatory drugs. Drug Intell Clin Pharm 1986, 20:925-934.
23. Gunnarsson I., Forslid J., Ringertz B. Mesalazine-induced lupus syndrome. Lupus 1999, 8:486-488.
24. Farrell R.J., Peppercorn M.A., Fine S.N., Michetti P. Mesalamine-associated thrombocytopenia. Am J Gastroenterol 1999, 94:2304-2306.
25. Deltenre P., Berson A., Marcellin P., Degott C., Biour M., Pessayre D. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut 1999, 44:886-888.
26. Gillet P., Nameche J. Hemolytic anemia induced by autoantibodies appearing in the course of para-amino-salicylic acid therapy. Acta Paediatr Belg 1967, 21:133-144.
27. Angeles M.L., Reid M.E., Yacob U.A., Cash K.L., Fetten J.V. Sulindac-induced immune hemolytic anemia. Transfusion 1994, 34:255-258.
28. Mintz P.D., Anderson G., Clark S. Immune hemolytic anemia associated with sulindac. Arch Intern Med 1986, 146:1639.
29. Bray V.J., West S.G., Schultz K.T., Boumpas D.T., Rubin R.L. Antihistone antibody profile in sulfasalazine induced lupus. JRheumatol 1994, 21:2157-2158.
30. Mielke H., Wildhagen K., Mau W., Zeidler H. Follow-up of patients with double stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases. Scand J Rheumatol 1993, 22:299-301.
31. Larsen J.R., Becher J.W. Fatal fulminant autoimmune haemolytic anaemia associated with tolmetin use and gastric carcinoma. Case report and literature review. Drug Saf 1993, 8:169-178.
32. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Med (Baltimore) 2007, 86:242-251.
33. Martin J.M., Ricart J.M., Alcacer J., Rausell N., Arana G. Adalimumab-induced lupus erythematosus. Lupus 2008, 17:676-678.
34. Sokumbi O., Wetter D.A., Makol A., Warrington K.J. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc 2012, 87:739-745.
35. Shakoor N., Michalska M., Harris C.A., Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359:579-580.
36. Mohan N., Edwards E.T., Cupps T.R., Slifman N., Lee J.H., Siegel J.N., et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. JRheumatol 2004, 31:1955-1958.
37. Phillips K., Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum 2005, 53:618-620.
38. Gonzalez-Lopez M.A., Blanco R., Gonzalez-Vela M.C., Fernandez-Llaca H., Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006, 55:817-820.
39. Lee A., Kasama R., Evangelisto A., Elfenbein B., Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. JClin Rheumatol 2006, 12:249-251.
40. Jarrett S.J., Cunnane G., Conaghan P.G., Bingham S.J., Buch M.H., Quinn M.A., et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. JRheumatol 2003, 30:2287-2291.
41. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004, 33:276-277.
42. Ronnblom L.E., Alm G.V., Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991, 115:178-183.
43. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. NEngl J Med 2006, 354:709-718.
44. Rotondi M., Oliviero A., Profice P., Mone C.M., Biondi B., Del Buono A., et al. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. JEndocrinol Invest 1998, 21:748-752.
45. Bonaci-Nikolic B., Jeremic I., Andrejevic S., Sefik-Bukilica M., Stojsavljevic N., Drulovic J. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus 2009, 18:78-80.
46. Szilasiova J., Gdovinova Z., Jautova J., Baloghova J., Ficova M., Bohus P. Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis. Clin Neuropharmacol 2009, 32:301-303.
47. Atkins M.B., Mier J.W., Parkinson D.R., Gould J.A., Berkman E.M., Kaplan M.M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. NEngl J Med 1988, 318:1557-1563.
48. Massarotti E.M., Liu N.Y., Mier J., Atkins M.B. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992, 92:693-697.
49. Bigazzi P.E. Autoimmunity and heavy metals. Lupus 1994, 3:449-453.
50. Baroni A., Puca R.V., Aiello F.S., Palla M., Faccenda F., Vozza G., et al. Cefuroxime-induced pemphigus erythematosus in a young boy. Clin Exp Dermatol 2009, 34:708-710.
51. Uz E., Bavbek N., Turgut F.H., Kanbay M., Kaya A., Akcay A. Cefuroxime-induced lupus. JNatl Med Assoc 2007, 99:1066-1067.
52. Salazar-Paramo M., Rubin R.L., Garcia-De La Torre I. Systemic lupus erythematosus induced by isoniazid. Ann Rheum Dis 1992, 51:1085-1087.
53. Gaultier C., Griscelli C., Hayem F., Plus A., Mozziconacci P. Lupus induced by isoniazid. Ann Pediatr 1972, 19:459-468.
54. Robinson M.G., Foadi M. Hemolytic anemia with positive Coombs' test. Association with isoniazid therapy. JAm Med Assoc 1969, 208:656-658.
55. Lawson T.M., Amos N., Bulgen D., Williams B.D. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001, 40:329-335.
56. Herzog D., Hajoui O., Russo P., Alvarez F. Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci 1997, 42:1100-1103.
57. Lenert P., Icardi M., Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. Clin Rheumatol 2013, 32:1099-1106.
58. Rubinstein A. LE-like disease caused by nalidixic acid. NEngl J Med 1979, 301:1288.
59. Tafani O., Mazzoli M., Landini G., Alterini B. Fatal acute immune haemolytic anaemia caused by nalidixic acid. Br Med J 1982, 285:936-937.
60. Peedikayil M.C., Dahhan T.I., Al Ashgar H.I. Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. Ann Pharmacother 2006, 40:1888-1889.
61. Bertoglio Cruzat J.C. Immune hemolytic anemia induced by penicillin. Rev Med Chil 1986, 114:1088-1089.
62. Layer P., Engelhard M. Tuberculostatics-induced systemic lupus erythematosus. Dtsch Med Wochenschr 1986, 111:1603-1605.
63. Letona J.M., Barbolla L., Frieyro E., Bouza E., Gilsanz F., Fernandez M.N. Immune haemolytic anaemia and renal failure induced by streptomycin. Br J Haematol 1977, 35:561-571.
64. Rallison M.L., O'Brien J., Good R.A. Severe reactions to long-acting sulfonamides. Erythema multiforme exudativum and lupus erythematosus following administration of sulfamethoxypyridazine and sulfadimethoxine. Pediatrics 1961, 28:908-917.
65. Lee S.H., Yoon J., Kim T.H., Um S.H., Yoon T.J. Systemic lupus erythematosus induced by tetracycline. Int J Dermatol 2013, 52:257-258.
66. Kelly J.R., Andolsek K. Tetracycline toxicity presenting as generalized vasculitis. South Med J 1978, 71:961-963.
67. Simpson M.B., Pryzbylik J., Innis B., Denham M.A. Hemolytic anemia after tetracycline therapy. NEngl J Med 1985, 312:840-842.
68. Shinskii G.E., Timofeeva E.D. The development of lupus erythematosus in patients with dermatomycoses treated with griseofulvin. Sov Med 1968, 31:92-93.
69. Rosa-Re D., Garcia F., Gascon J., Angrill J., Cervera R. Quinine induced lupus-like syndrome and cardiolipin antibodies. Ann Rheum Dis 1996, 55:559-560.
70. Price E.J., Bevan J.S., Rees A. Quinine-induced cutaneous vasculitis. Br J Clin Pract 1992, 46:138-139.
71. Bougie D.W., Wilker P.R., Aster R.H. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 2006, 108:922-927.
72. Bernstein R.E. Procainamide, acetylprocainamide, and drug-induced lupus erythematosus. Lancet 1979, 2:1076.
73. Ladd A.T. Procainamide-induced lupus erythematosus. NEngl J Med 1962, 267:1357-1358.
74. Mongey A.B., Donovan-Brand R., Thomas T.J., Adams L.E., Hess E.V. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992, 35:219-223.
75. Guindo J., Rodriguez de la Serna A., Borja J., Oter R., Jane F., Bayes de Luna A. Propafenone and a syndrome of the lupus erythematosus type. Ann Intern Med 1986, 104:589.
76. West S.G., McMahon M., Portanova J.P. Quinidine-induced lupus erythematosus. Ann Intern Med 1984, 100:840-842.
77. Fenniche S., Dhaoui A., Ammar F.B., Benmously R., Marrak H., Mokhtar I. Acebutolol-induced subacute cutaneous lupus erythematosus. Skin Pharmacol Physiol 2005, 18:230-233.
78. Hourdebaigt-Larrusse P., Ziza J.M., Grivaux M. Anew case of lupus induced by acebutolol. Ann Cardiol Angeiol (Paris) 1985, 34:421-423.
79. McGuiness M., Frye R.A., Deng J.S. Atenolol-induced lupus erythematosus. JAm Acad Dermatol 1997, 37:298-299.
80. Bertin P., Kamdem J., Bonnet C., Arnaud M., Treves R. Captopril-induced lupus. Clin Exp Rheumatol 1993, 11:695.
81. Pujol M., Duran-Suarez J.R., Martin Vega C., Sanchez C., Tovar J.L., Valles M. Autoimmune thrombocytopenia in three patients treated with captopril. Vox Sang 1989, 57:218.
82. Berthelot J.M., Moreau A., Glemarec J., Mussini J.M., Maugars Y., Prost A. Enalapril-induced vasculitis resembling rheumatoid arthritis, lupus, sicca syndrome, and giant cell arteritis. Rev Rheum Engl Ed 1997, 64:421-423.
83. Batchelor J.R., Welsh K.I., Tinoco R.M., Dollery C.T., Hughes G.R., Bernstein R., et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1980, 1:1107-1109.
84. Brown R.C., Cooke J., Losowsky M.S. SLE syndrome, probably induced by labetalol. Postgrad Med J 1981, 57:189-190.
85. Paladini G. Peyronie's disease and systemic lupus erythematosus syndrome associated with metoprolol administration: a case report. Int J Tissue React 1981, 3:95-98.
86. Homberg J.C., Abuaf N., Plouin P.F., Menard J., Fillastre J.P. Antinuclear antibodies and lupus induced during treatment of arterial hypertension. Role of beta-blockers and alpha-methyldopa. JPharmacol 1983, 14(Suppl.2):61-66.
87. Stewart M.W., Clarke S.W. Practolol-induced SLE-like syndrome. Proc R Soc Med 1976, 69:61-62.
88. Harrison T., Sisca T.S., Wood W.H. Case report. Propranolol-induced lupus syndrome?. Postgrad Med 1976, 59:241-244.
89. Uddin M.S., Lynfield Y.L., Grosberg S.J., Stiefler R. Cutaneous reaction to spironolactone resembling lupus erythematosus. Cutis 1979, 24:198-200.
90. Zamber R.W., Starkebaum G., Rubin R.L., Martens H.F., Wener M.H. Drug induced systemic lupus erythematosus due to ophthalmic timolol. JRheumatol 1992, 19:977-979.
91. Witman G., Davis R. Alupus erythematosus syndrome induced by clonidine hydrochloride. RI Med J 1981, 64:147-150.
92. McCraken M., Benson E.A., Hickling P. Systemic lupus erythematosus induced by aminoglutethimide. Br Med J 1980, 281:1254.
93. Laroche M., Borg S., Lassoued S., De Lafontan B., Roche H. Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. JRheumatol 2007, 34:2259-2263.
94. Mehta J., Singhal S., Revankar R., Walvalkar A., Chablani A., Mehta B.C. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1. Lancet 1991, 337:298.
95. Thual N., Penven K., Chevallier J.M., Dompmartin A., Leroy D. Fluvastatin-induced dermatomyositis. Ann Dermatol Venereol 2005, 132:996-999.
96. Stoebner P.E., Michot C., Ligeron C., Durand L., Meynadier J., Meunier L. Simvastatin-induced lichen planus pemphigoides. Ann Dermatol Venereol 2003, 130:187-190.
97. Fretwell M.D., Altman L.C. Exacerbation of a lupus-erythematosus-like syndrome during treatment of non-C1-esterase-inhibitor-dependent angioedema with danazol. JAllergy Clin Immunol 1982, 69:306-310.
98. Wiechert A., Tuting T., Bieber T., Haidl G., Wenzel J. Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. Br J Dermatol 2008, 159:231-233.
99. Haller M., Schatz D. The role of leuprolide acetate therapy in triggering auto-immune thyroiditis. JPediatr 2005, 146:294. author reply - 5.
100. Takuwa N., Kojima I., Ogata E. Lupus-like syndrome - a rare complication in thionamide treatment for Graves' disease. Endocrinol Jpn 1981, 28:663-667.
101. Vachtenheim J., Vykouril J. Methylthiouracil as a provocative factor in systemic lupus erythematosus. Cas Lek Cesk 1963, 102:1413-1416.
102. Schoonen W.M., Thomas S.L., Somers E.C., Smeeth L., Kim J., Evans S., et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol 2010, 70:588-596.
103. Atwater B.D., Ai Z., Wolff M.R. Fulminant myopericarditis from phenytoin-induced systemic lupus erythematosus. WMJ 2008, 107:298-300.
104. Acostamadiedo J.M., Perniciaro C., Rogers R.S. Phenytoin-induced linear IgA bullous disease. JAm Acad Dermatol 1998, 38:352-356.
105. Crespel A., Velizarova R., Agullo M., Gelisse P. Ethosuximide-induced de novo systemic lupus erythematosus with anti-double-strand DNA antibodies: a case report with definite evidence. Epilepsia 2009, 50:2003.
106. Drory V.E., Korczyn A.D. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol 1993, 16:19-29.
107. Garcia-Morteo O., Maldonado-Cocco J.A. Lupus-like syndrome during treatment with nomifensine. Arthritis Rheum 1983, 26:936.
108. Swartz C. Lupus-like reaction to phenelzine. JAm Med Assoc 1978, 239:2693.
109. Graham J.R. Drug-induced localized systemic scleroses. Trans Am Clin Climatol Assoc 1981, 92:122-132.
110. Linstrom F.D., Lieden G., Enstrom M.S. Dose-related levodopa-induced haemolytic anaemia. Ann Intern Med 1977, 86:298-300.
111. Wanamaker W.M., Wanamaker S.J., Celesia G.G., Koeller A.A. Thrombocytopenia associated with long-term levodopa therapy. JAm Med Assoc 1976, 235:2217-2219.
112. Massarotti G., Cassi E., Passaleva A. Lupus-like autoimmune syndrome after levodopa and benserazide. Br Med J 1979, 2:553.
113. Hieronymus T., Grotsch P., Blank N., Grunke M., Capraru D., Geiler T., et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus?. Arthritis Rheum 2000, 43:1994-2004.
114. McNevin S., MacKay M. Chlorprothixene-induced systemic lupus erythematosus. JClin Psychopharmacol 1982, 2:411-412.
115. Fletcher A.J. Levomepromazine-induced lupus?. JPain Symptom Manage 2009, 37:e1-2.
116. Steen V.D., Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum 1988, 31:923-926.
117. Gelmers H.J. Exacerbation of systemic lupus erythematosus, aseptic meningitis and acute mental symptoms, following metrizamide lumbar myelography. Neuroradiology 1984, 26:65-66.
118. Tunkel A.R., Shuman M., Popkin M., Seth R., Hoffman B. Minoxidil-induced systemic lupus erythematosus. Arch Intern Med 1987, 147:599-600.
119. Reynolds T.B., Peters R.L., Yamada S. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. NEngl J Med 1971, 285:813-820.
120. Eyanson S., Greist M.C., Brandt K.D., Skinner B. Systemic lupus erythematosus: association with psoralen-ultraviolet - a treatment of psoriasis. Arch Dermatol 1979, 115:54-56.
121. Selmi C., Crotti C., Meroni P.L. Less travelled roads in clinical immunology and allergy: drug reactions and the environmental influence. Clin Rev Allergy Immunol 2013, 45:1-5.
122. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. JAutoimmun 2012, 39:272-284.
123. Pollard K.M. Gender differences in autoimmunity associated with exposure to environmental factors. JAutoimmun 2012, 38:J177-J186.